Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’ Sophie Chansophie.chan@legalease.co.uk9 February 2024ProfileLife Sciences Yearbook 2024 David Gibson, senior associate at McDermott Will & EmeryWhy did you decide to specialise in life sciences law, and what’s the best thing about being a life sciences lawyer?Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact jasmine.glass@legalbusiness.co.uk Related ContentRevolving Doors: Paul Hastings picks up White & Case infra team while Bakers makes double hire in London‘Setting ourselves up for the future’ – McDermott ups London trainee pay to £70kMcDermott snaps up CMS international private equity co-head in LondonM&A perspectives: Lorenzo CorteM&A perspectives: Melissa FogartyM&A perspectives: Jennifer BethlehemRising stars: Dr Chris Boyle – ‘AI is going to have a transformative impact on the life sciences industry’The Legal 500 view: Healthy competitionLife Sciences Yearbook 2024 – Editor’s letter